(Q79215184)
Statements
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) (English)
L Perey
R Paridaens
H Hawle
K Zaman
F Nolé
H Wildiers
M Fiche
D Dietrich
P Clément
D Köberle
A Goldhirsch
B Thürlimann
9 October 2006